Segall Bryant & Hamill LLC Raises Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Segall Bryant & Hamill LLC lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 1.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 120,301 shares of the company’s stock after acquiring an additional 1,739 shares during the period. Segall Bryant & Hamill LLC’s holdings in Protagonist Therapeutics were worth $5,414,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of PTGX. GAMMA Investing LLC lifted its position in Protagonist Therapeutics by 749.2% during the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after acquiring an additional 487 shares during the period. Exchange Traded Concepts LLC acquired a new stake in shares of Protagonist Therapeutics during the third quarter worth $43,000. Russell Investments Group Ltd. acquired a new stake in shares of Protagonist Therapeutics during the first quarter worth $35,000. CWM LLC grew its position in Protagonist Therapeutics by 910.3% in the 3rd quarter. CWM LLC now owns 1,273 shares of the company’s stock valued at $57,000 after buying an additional 1,147 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Protagonist Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock valued at $95,000 after buying an additional 379 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Protagonist Therapeutics news, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the transaction, the director now directly owns 12,000 shares in the company, valued at approximately $540,000. This represents a 40.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the sale, the chief financial officer now owns 34,960 shares of the company’s stock, valued at approximately $1,555,370.40. This trade represents a 28.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,109 shares of company stock worth $1,069,999 in the last three months. Corporate insiders own 5.40% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. JMP Securities lowered their target price on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 7th. StockNews.com raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. TD Cowen upgraded Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. Wedbush reissued an “outperform” rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $53.57.

Protagonist Therapeutics Price Performance

PTGX opened at $46.46 on Friday. Protagonist Therapeutics, Inc. has a 1-year low of $16.80 and a 1-year high of $48.89. The stock has a market cap of $2.77 billion, a P/E ratio of 17.47 and a beta of 2.17. The stock’s 50 day simple moving average is $45.26 and its 200 day simple moving average is $39.02.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.